OncoSec Medical (NASDAQ:ONCS) Given a $6.00 Price Target by Maxim Group Analysts

Maxim Group set a $6.00 price objective on OncoSec Medical (NASDAQ:ONCS) in a research note published on Wednesday morning, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

ONCS has been the topic of a number of other research reports. ValuEngine raised shares of OncoSec Medical from a hold rating to a buy rating in a research note on Thursday. Zacks Investment Research cut shares of OncoSec Medical from a buy rating to a hold rating in a research note on Wednesday, July 24th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $19.75.

OncoSec Medical stock traded down $0.06 during trading on Wednesday, reaching $2.11. The company had a trading volume of 139,297 shares, compared to its average volume of 122,263. The company has a 50-day moving average of $2.46. OncoSec Medical has a 1-year low of $2.02 and a 1-year high of $19.60.

In related news, Director Alpha Holdings, Inc. purchased 90,000 shares of OncoSec Medical stock in a transaction dated Tuesday, July 16th. The shares were acquired at an average price of $2.30 per share, for a total transaction of $207,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 5.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in OncoSec Medical by 484.1% in the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 83,150 shares during the last quarter. Northern Trust Corp lifted its stake in OncoSec Medical by 33.6% in the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 28,914 shares during the last quarter. Geode Capital Management LLC lifted its stake in OncoSec Medical by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 163,405 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in OncoSec Medical by 98.2% in the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after buying an additional 240,843 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Featured Article: What is a death cross?

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.